- Home
- TLN vs INCY Comparison
TLN vs INCY Comparison
Compare TLN & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLN
- INCY
- Stock Information
- Founded
- TLN 2015
- INCY 1991
- Country
- TLN United States
- INCY United States
- Employees
- TLN 1894
- INCY N/A
- Industry
- TLN Electric Utilities: Central
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- TLN Utilities
- INCY Health Care
- Exchange
- TLN Nasdaq
- INCY Nasdaq
- Market Cap
- TLN 19.7B
- INCY 17.0B
- IPO Year
- TLN N/A
- INCY 1993
- Fundamental
- Price
- TLN $432.70
- INCY $86.60
- Analyst Decision
- TLN Strong Buy
- INCY Buy
- Analyst Count
- TLN 12
- INCY 20
- Target Price
- TLN $376.50
- INCY $80.67
- AVG Volume (30 Days)
- TLN 725.2K
- INCY 1.7M
- Earning Date
- TLN 11-13-2025
- INCY 10-28-2025
- Dividend Yield
- TLN N/A
- INCY N/A
- EPS Growth
- TLN N/A
- INCY 900.04
- EPS
- TLN 3.80
- INCY 4.37
- Revenue
- TLN $2,128,000,000.00
- INCY $4,584,996,000.00
- Revenue This Year
- TLN $11.82
- INCY $16.41
- Revenue Next Year
- TLN $79.55
- INCY $10.86
- P/E Ratio
- TLN $113.35
- INCY $19.96
- Revenue Growth
- TLN 1.09
- INCY 18.87
- 52 Week Low
- TLN $148.02
- INCY $53.56
- 52 Week High
- TLN $451.28
- INCY $88.66
- Technical
- Relative Strength Index (RSI)
- TLN 66.60
- INCY 59.14
- Support Level
- TLN $424.82
- INCY $85.18
- Resistance Level
- TLN $451.28
- INCY $88.27
- Average True Range (ATR)
- TLN 13.62
- INCY 1.89
- MACD
- TLN -0.26
- INCY 0.02
- Stochastic Oscillator
- TLN 61.10
- INCY 75.54
About TLN Talen Energy Corporation Common Stock
Talen Energy Corp is an independent power producer and energy infrastructure company. The company owns and operates approximately 10.7 gigawatts of power infrastructure in the United States. The group produces and sells electricity, capacity, and ancillary services into wholesale U.S. power markets, including PJM and WECC, with its generation fleet located in the Mid-Atlantic and Montana.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.